Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florence Pedeutour

Showing results (91-100 of 101) with videos related to

Pageof 11
Sort By:
International Journal of Cancer|January 25, 2008
HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent ampliconAntoine Italiano, Laurence Bianchini, Frédérique Keslair, et al.
Cancers|October 23, 2020
Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual TargetingBérengère Dadone-Montaudié, Audrey Laroche-Clary, Aline Mongis, et al.
The Journal of Investigative Dermatology|September 21, 2020
A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma ProtuberansJulie Delyon, Raphael Porcher, Maxime Battistella, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 5, 2015
Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomasEsma Saâda-Bouzid, Fanny Burel-Vandenbos, Dominique Ranchère-Vince, et al.
Cancer Research|May 25, 2013
Autophagy plays a critical role in the degradation of active RHOA, the control of cell cytokinesis, and genomic stabilityAmine Belaid, Michaël Cerezo, Abderrahman Chargui, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2010
Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patientsDelphine Kérob, Raphael Porcher, Olivier Vérola, et al.
The Lancet. Oncology|March 14, 2016
Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): a prospective, multicentre, observational studyAntoine Italiano, Ilaria Di Mauro, Jocelyn Rapp, et al.
Histopathology|May 14, 2022
Comprehensive study of nine novel cases of TFEB-amplified renal cell carcinoma: an aggressive tumour with frequent PDL1 expressionSolène-Florence Kammerer-Jacquet, Camille Gandon, Frederic Dugay, et al.
Cancer Cell|December 18, 2014
The architecture and evolution of cancer neochromosomesDale W Garsed, Owen J Marshall, Vincent D A Corbin, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 30, 2018
Alternative PDGFD rearrangements in dermatofibrosarcomas protuberans without PDGFB fusionsBérengère Dadone-Montaudié, Laurent Alberti, Adeline Duc, et al.
Pageof 11

Showing results (91-100 of 101) with videos related to

Sort By:
Pageof 11
International Journal of Cancer|January 25, 2008
HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent ampliconAntoine Italiano, Laurence Bianchini, Frédérique Keslair, et al.
Cancers|October 23, 2020
Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual TargetingBérengère Dadone-Montaudié, Audrey Laroche-Clary, Aline Mongis, et al.
The Journal of Investigative Dermatology|September 21, 2020
A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma ProtuberansJulie Delyon, Raphael Porcher, Maxime Battistella, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 5, 2015
Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomasEsma Saâda-Bouzid, Fanny Burel-Vandenbos, Dominique Ranchère-Vince, et al.
Cancer Research|May 25, 2013
Autophagy plays a critical role in the degradation of active RHOA, the control of cell cytokinesis, and genomic stabilityAmine Belaid, Michaël Cerezo, Abderrahman Chargui, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 5, 2010
Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patientsDelphine Kérob, Raphael Porcher, Olivier Vérola, et al.
The Lancet. Oncology|March 14, 2016
Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): a prospective, multicentre, observational studyAntoine Italiano, Ilaria Di Mauro, Jocelyn Rapp, et al.
Histopathology|May 14, 2022
Comprehensive study of nine novel cases of TFEB-amplified renal cell carcinoma: an aggressive tumour with frequent PDL1 expressionSolène-Florence Kammerer-Jacquet, Camille Gandon, Frederic Dugay, et al.
Cancer Cell|December 18, 2014
The architecture and evolution of cancer neochromosomesDale W Garsed, Owen J Marshall, Vincent D A Corbin, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|June 30, 2018
Alternative PDGFD rearrangements in dermatofibrosarcomas protuberans without PDGFB fusionsBérengère Dadone-Montaudié, Laurent Alberti, Adeline Duc, et al.
Pageof 11